Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04471727 · ClinicalTrials.gov registry record · Phase 1

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

A Phase 1 study of Small-cell Lung Cancer and Neuroendocrine Carcinoma, sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

Active
Registry status
Phase 1
Development phase
232
Enrollment target
11
Study locations

NCT04471727: Active Phase 1 study of Small-cell Lung Cancer and Neuroendocrine Carcinoma, sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

NCT04471727 is a Phase 1 study of Small-cell Lung Cancer and Neuroendocrine Carcinoma that is active but no longer recruiting, run by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 232 participants, roughly in line with the 229-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target. The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04471727, a Phase 1 study of Small-cell Lung Cancer and Neuroendocrine Carcinoma, is active but no longer recruiting, sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
232 participants
Enrollment target
11
Study locations

Study Summary

This study will investigate the maximum tolerated dose, the recommended dose for expansion (RDE), safety, efficacy, and pharmacokinetics of gocatamig alone, gocatamig with Atezolizumab and gocatamig with I-DXd in participants with advanced cancers associated with expression of Delta-like Canonical Notch Ligand 3 (DLL3).

Primary Outcome

An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. AEs will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTACAE) versio

Conditions Studied

Small-cell Lung Cancer Neuroendocrine Carcinoma

Interventions

  • BIOLOGICAL Atezolizumab
  • BIOLOGICAL Gocatamig
  • BIOLOGICAL Ifinatamab Deruxtecan (I-DXd)

Study Locations (11)

California

  • Cedar-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute - Los Angeles
  • University of California San Francisco - San Francisco

New York

  • Roswell Park Comprehensive Cancer Center - Buffalo
  • Memorial Sloan Kettering Cancer Center - New York

Colorado

  • University of Colorado - Aurora

Massachusetts

  • Dana Farber Cancer Institute - Boston

Michigan

  • Karmanos Cancer Center - Detroit

Ohio

  • University Hospitals Cleveland Medical Center - Cleveland

Oregon

  • Providence - Portland

Tennessee

  • Tennessee Oncology - Nashville

Trial Details

FieldValue
Enrollment Target 232 participants
Start Date 2020-12-14
Est. Completion 2028-01-28
Phase Phase 1
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

4 total trials

What the registry record for NCT04471727 still lists

NCT04471727 is an interventional study that assigns participants to a tested intervention. The registered 232 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 229-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target.

The record links to 2 conditions, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Atezolizumab is the first listed.

NCT04471727 lists 11 locations in 9 states (California, New York, Colorado).

Frequently Asked Questions

What is clinical trial NCT04471727 about?

NCT04471727 is a clinical study titled "A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)". This study will investigate the maximum tolerated dose, the recommended dose for expansion (RDE), safety, efficacy, and pharmacokinetics of gocatamig alone, gocatamig with Atezolizumab and gocatamig with I-DXd in participants with advanced cancers associated with expression of Delta-like Canonical N...

What is the current status of trial NCT04471727?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 232 participants. The study started on 2020-12-14. Estimated completion is 2028-01-28.

What conditions does trial NCT04471727 study?

This clinical trial studies the following conditions: Small-cell Lung Cancer, Neuroendocrine Carcinoma.

What interventions are being tested in trial NCT04471727?

The interventions under investigation include: Atezolizumab (BIOLOGICAL), Gocatamig (BIOLOGICAL), Ifinatamab Deruxtecan (I-DXd) (BIOLOGICAL).

Who is sponsoring clinical trial NCT04471727?

This trial is sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04471727 being conducted?

This trial has 11 study locations across California, Colorado, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Small-cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04471727's enrollment target sits among peer trials

232 24th of 79 higher than 56 of 79 other Small-cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01356290 · 232 participants · Phase 2

    Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

  • NCT04753359 · 232 participants · NA

    Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer

  • NCT04770870 · 232 participants · NA

    Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System

  • NCT05948943 · 232 participants · Phase 2

    Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04471727, the US trial registry maintained by the National Library of Medicine. NCT04471727 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.